Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02000596
Title Trastuzmab and Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Katherine Tkaczuk

Her2-receptor positive breast cancer


Pertuzumab + Trastuzumab

Anastrozole + Fulvestrant

Age Groups: senior
Covered Countries USA

No variant requirements are available.